{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:26:55Z","timestamp":1785882415550,"version":"3.56.0"},"reference-count":132,"publisher":"Portland Press Ltd.","issue":"11","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Diabetes increases the prevalence of heart failure by 6\u20138-fold, independent of other comorbidities such as hypertension and coronary artery disease, a phenomenon termed diabetic cardiomyopathy. Several key signalling pathways have been identified that drive the pathological changes associated with diabetes-induced heart failure. This has led to the development of multiple pharmacological agents that are currently available for clinical use. While fairly effective at delaying disease progression, these treatments do not reverse the cardiac damage associated with diabetes. One potential alternative avenue for targeting diabetes-induced heart failure is the use of adeno-associated viral vector (AAV) gene therapy, which has shown great versatility in a multitude of disease settings. AAV gene therapy has the potential to target specific cells or tissues, has a low host immune response and has the possibility to represent a lifelong cure, not possible with current conventional pharmacotherapies. In this review, we will assess the therapeutic potential of AAV gene therapy as a treatment for diabetic cardiomyopathy.<\/jats:p>","DOI":"10.1042\/cs20210052","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T09:20:48Z","timestamp":1622625648000},"page":"1369-1387","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy \u2013 current and future perspectives"],"prefix":"10.1042","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-6478","authenticated-orcid":false,"given":"Darnel","family":"Prakoso","sequence":"first","affiliation":[{"name":"Departments of Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University Parkville Campus, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchel","family":"Tate","sequence":"additional","affiliation":[{"name":"Departments of Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University Parkville Campus, Australia"},{"name":"Diabetes, Monash University, Clayton, Victoria 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles\u00a0J.\u00a0De","family":"Blasio","sequence":"additional","affiliation":[{"name":"Departments of Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University Parkville Campus, Australia"},{"name":"Pharmacology, Monash University, Clayton, Victoria 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-0058","authenticated-orcid":false,"given":"Rebecca\u00a0H.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Departments of Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University Parkville Campus, Australia"},{"name":"Diabetes, Monash University, Clayton, Victoria 3800, Australia"},{"name":"Pharmacology, Monash University, Clayton, Victoria 3800, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"2021113011215288700_B1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2021113011215288700_B2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2215\/CJN.00540705","article-title":"Heart failure and nephropathy: catastrophic and interrelated complications of diabetes","volume":"1","author":"Gilbert","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2021113011215288700_B3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur. Heart J."},{"key":"2021113011215288700_B4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am. J. Cardiol."},{"key":"2021113011215288700_B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am. J. Cardiol."},{"key":"2021113011215288700_B6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011215288700_B7","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ. Res."},{"key":"2021113011215288700_B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/IJICMR.S21679","article-title":"The role of inflammation in diabetic cardiomyopathy","volume":"4","author":"Reis","year":"2012","journal-title":"Int. J. Interferon. Cytokine. Mediat. Res."},{"key":"2021113011215288700_B9","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.2337\/db11-0549","article-title":"TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model","volume":"60","author":"Ti","year":"2011","journal-title":"Diabetes"},{"key":"2021113011215288700_B10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/BF02912887","article-title":"Diabetic cardiomyopathy and reactive oxygen species (ROS) related parameters in male and female rats: a comparative study","volume":"22","author":"Akhileshwar","year":"2007","journal-title":"Indian J. Clin. Biochem."},{"key":"2021113011215288700_B11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0022-2828(81)90318-7","article-title":"Depressed cardiac sarcoplasmic reticular function from diabetic rats","volume":"13","author":"Penpargkul","year":"1981","journal-title":"J. Mol. Cell Cardiol."},{"key":"2021113011215288700_B12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2337\/diabetes.55.03.06.db05-1284","article-title":"Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db\/db type 2 diabetic mice","volume":"55","author":"Pereira","year":"2006","journal-title":"Diabetes"},{"key":"2021113011215288700_B13","article-title":"Role of O-linked N-acetylglucosamine (O-GlcNAc) protein modification in cellular (patho)physiology","author":"Chatham","year":"2020","journal-title":"Physiol. Rev."},{"key":"2021113011215288700_B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10409238.2015.1135102","article-title":"New insights: a role for O -GlcNAcylation in diabetic complications","volume":"9238","author":"Peterson","year":"2016","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"2021113011215288700_B15","doi-asserted-by":"publisher","first-page":"R689","DOI":"10.1152\/ajpregu.00548.2011","article-title":"Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy","volume":"303","author":"Fricovsky","year":"2012","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"2021113011215288700_B16","doi-asserted-by":"publisher","first-page":"14500","DOI":"10.1038\/srep14500","article-title":"O-GlcNAcylation regulates ischemia-induced neuronal apoptosis through AKT signaling","volume":"5","author":"Shi","year":"2015","journal-title":"Sci. Rep."},{"key":"2021113011215288700_B17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"2021113011215288700_B18","doi-asserted-by":"publisher","first-page":"H768","DOI":"10.1152\/ajpheart.00038.2005","article-title":"Cardiomyocyte apoptosis induced by short-term diabetes requires mitochondrial GSH depletion","volume":"289","author":"Ghosh","year":"2005","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"2021113011215288700_B19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejcts.2006.07.006","article-title":"The relationship between myocardial extracellular matrix remodeling and ventricular function","volume":"30","author":"Brower","year":"2006","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"2021113011215288700_B20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2337\/db06-1163","article-title":"Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism","volume":"56","author":"Westermann","year":"2007","journal-title":"Diabetes"},{"key":"2021113011215288700_B21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"2021113011215288700_B22","doi-asserted-by":"publisher","first-page":"e12340","DOI":"10.1111\/micc.12340","article-title":"Current perspectives in coronary microvascular dysfunction","volume":"24","author":"Shome","year":"2017","journal-title":"Microcirculation"},{"key":"2021113011215288700_B23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-018-0703-2","article-title":"Diabetes, cardiovascular disease and the microcirculation","volume":"17","author":"Strain","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113011215288700_B24","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.104.503433","article-title":"Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells","volume":"112","author":"Yoon","year":"2005","journal-title":"Circulation"},{"key":"2021113011215288700_B25","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021113011215288700_B26","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021113011215288700_B27","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet Lond. Engl."},{"key":"2021113011215288700_B28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1161\/CIRCHEARTFAILURE.110.952556","article-title":"Metformin use and mortality in ambulatory patients with diabetes and heart failure","volume":"4","author":"Aguilar","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"2021113011215288700_B29","doi-asserted-by":"publisher","first-page":"d1309","DOI":"10.1136\/bmj.d1309","article-title":"Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies","volume":"342","author":"Loke","year":"2011","journal-title":"BMJ"},{"key":"2021113011215288700_B30","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00125-019-4958-2","article-title":"Clinical aspects of heart failure in individuals with diabetes","volume":"62","author":"Bowes","year":"2019","journal-title":"Diabetologia"},{"key":"2021113011215288700_B31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diab. Endocrinol."},{"key":"2021113011215288700_B32","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2021113011215288700_B33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care."},{"key":"2021113011215288700_B34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.pcad.2019.08.003","article-title":"Cardiovascular outcome trials of the newer anti-diabetic medications","volume":"62","author":"Acharya","year":"2019","journal-title":"Prog. Cardiovasc. Dis."},{"key":"2021113011215288700_B35","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ejhf.1673","article-title":"European society of cardiology\/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"2021113011215288700_B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2021113011215288700_B37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2021113011215288700_B38","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"2021113011215288700_B39","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1161\/CIRCRESAHA.112.278820","article-title":"An emerging strategy of gene therapy for cardiac disease","volume":"111","author":"Yoshida","year":"2012","journal-title":"Circ. Res."},{"key":"2021113011215288700_B40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1172\/JCI62837","article-title":"Potential of gene therapy as a treatment for heart failure","volume":"123","author":"Hajjar","year":"2013","journal-title":"J. Clin. Invest."},{"key":"2021113011215288700_B41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1161\/CIRCRESAHA.111.252981","article-title":"Gene therapy for heart failure","volume":"110","author":"Tilemann","year":"2012","journal-title":"Circ. Res."},{"key":"2021113011215288700_B42","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur. Heart J."},{"key":"2021113011215288700_B43","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2010.11.023","article-title":"Rescuing the failing heart by targeted gene transfer","volume":"57","author":"Kawase","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011215288700_B44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1517\/14712598.2014.866085","article-title":"Cardiovascular gene therapy for myocardial infarction","volume":"14","author":"Scimia","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"2021113011215288700_B45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"2021113011215288700_B46","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/mt.2011.124","article-title":"AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities","volume":"19","author":"Pacak","year":"2011","journal-title":"Mol. Ther."},{"key":"2021113011215288700_B47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11886-012-0333-3","article-title":"Gene therapy for heart failure: where do we stand?","volume":"15","author":"Naim","year":"2013","journal-title":"Curr. Cardiol. Rep."},{"key":"2021113011215288700_B48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"2021113011215288700_B49","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol. Ther."},{"key":"2021113011215288700_B50","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"2021113011215288700_B51","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021113011215288700_B52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ymthe.2003.10.013","article-title":"Chance or necessity? Insertional mutagenesis in gene therapy and its consequences","volume":"9","author":"Baum","year":"2004","journal-title":"Mol. Ther."},{"key":"2021113011215288700_B53","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur. Heart J."},{"key":"2021113011215288700_B54","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"key":"2021113011215288700_B55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1752-8062.2010.00190.x","article-title":"Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart","volume":"3","author":"Zincarelli","year":"2010","journal-title":"Clin. Transl. Sci."},{"key":"2021113011215288700_B56","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/hum.2017.229","article-title":"Translational aspects of adeno-associated virus-mediated cardiac gene therapy","volume":"29","author":"Ziegler","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"2021113011215288700_B57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/hmg\/ddz148","article-title":"Next-generation AAV vectors\u2014do not judge a virus (only) by its cover","volume":"28","author":"Domenger","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"2021113011215288700_B58","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/gt.2008.104","article-title":"Construction and analysis of compact muscle-specific promoters for AAV vectors","volume":"15","author":"Wang","year":"2008","journal-title":"Gene Ther."},{"key":"2021113011215288700_B59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/sj.gt.3301838","article-title":"Tetracycline-inducible transgene expression mediated by a single AAV vector","volume":"10","author":"Chtarto","year":"2003","journal-title":"Gene Ther."},{"key":"2021113011215288700_B60","doi-asserted-by":"publisher","first-page":"P091","DOI":"10.1186\/ar260","article-title":"Development of a doxycycline inducible AAV vector for long term in vivo viral IL-10 gene transfer in rheumatoid arthritis","volume":"3","author":"Apparailly","year":"2001","journal-title":"Arthritis Res. Ther."},{"key":"2021113011215288700_B61","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1161\/01.RES.0000065442.64694.9F","article-title":"Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter","volume":"92","author":"Sanbe","year":"2003","journal-title":"Circ. Res."},{"key":"2021113011215288700_B62","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/mt.2011.154","article-title":"AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice","volume":"19","author":"Bostick","year":"2011","journal-title":"Mol. Ther."},{"key":"2021113011215288700_B63","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1161\/hy0202.103472","article-title":"Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection","volume":"39","author":"Phillips","year":"2002","journal-title":"Hypertension"},{"key":"2021113011215288700_B64","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1161\/CIRCIMAGING.112.000320","article-title":"Cardiac-selective expression of extracellular superoxide dismutase after systemic injection of adeno-associated virus 9 protects the heart against post-myocardial infarction left ventricular remodeling","volume":"6","author":"Konkalmatt Prasad","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"2021113011215288700_B65","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","article-title":"Phosphoinositide 3-kinase p110\u03b1 is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction","volume":"5","author":"Weeks","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"2021113011215288700_B66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/CIRCRESAHA.118.313811","article-title":"Atrial-specific gene delivery using an adeno-associated viral vector","volume":"124","author":"Ni","year":"2019","journal-title":"Circ. Res."},{"key":"2021113011215288700_B67","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/gt.2012.8","article-title":"Targeting S100A1 in heart failure","volume":"19","author":"Ritterhoff","year":"2012","journal-title":"Gene Ther."},{"key":"2021113011215288700_B68","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/fca.15.18","article-title":"Cardiomyocytes, endothelial cells and cardiac fibroblasts: S100A1's triple action in cardiovascular pathophysiology","volume":"11","author":"Rohde","year":"2015","journal-title":"Fut. Cardiol."},{"key":"2021113011215288700_B69","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.106.671701","article-title":"Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue","volume":"115","author":"Pleger","year":"2007","journal-title":"Circulation"},{"key":"2021113011215288700_B70","doi-asserted-by":"publisher","first-page":"92ra64","DOI":"10.1126\/scitranslmed.3002097","article-title":"Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model","volume":"3","author":"Pleger","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2021113011215288700_B71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/gt.2013.63","article-title":"Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model","volume":"21","author":"Weber","year":"2014","journal-title":"Gene Ther."},{"key":"2021113011215288700_B72","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nature10407","article-title":"SUMO1-dependent modulation of SERCA2a in heart failure","volume":"477","author":"Kho","year":"2011","journal-title":"Nature"},{"key":"2021113011215288700_B73","doi-asserted-by":"publisher","first-page":"211ra159","DOI":"10.1126\/scitranslmed.3006487","article-title":"SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure","volume":"5","author":"Tilemann","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2021113011215288700_B74","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/mt.2014.127","article-title":"Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure","volume":"22","author":"Ishikawa","year":"2014","journal-title":"Mol. Ther."},{"key":"2021113011215288700_B75","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2017.97","article-title":"AAV-9 mediated phosphatase-1 inhibitor-1 overexpression improves cardiac contractility in unchallenged mice but is deleterious in pressure-overload","author":"Schwab","year":"2018","journal-title":"Gene Ther."},{"key":"2021113011215288700_B76","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.jacc.2017.08.013","article-title":"Protein phosphatase inhibitor-1 gene therapy in a swine model of nonischemic heart failure","volume":"70","author":"Watanabe","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011215288700_B77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jacbts.2017.12.004","article-title":"Effects of urocortin 2 versus urocortin 3 gene transfer on left ventricular function and glucose disposal","volume":"3","author":"Giamouridis","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"2021113011215288700_B78","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/hum.2014.157","article-title":"Intravenous AAV8 encoding urocortin-2 increases function of the failing heart in mice","volume":"26","author":"Lai","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"2021113011215288700_B79","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/hum.2018.103","article-title":"Urocortin 3 gene transfer increases function of the failing murine heart","volume":"30","author":"Giamouridis","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"2021113011215288700_B80","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/gt.2012.17","article-title":"VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond","volume":"19","author":"Giacca","year":"2012","journal-title":"Gene Ther."},{"key":"2021113011215288700_B81","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/mt.2012.145","article-title":"AAV9-mediated VEGF-B gene transfer Improves systolic function in progressive left ventricular hypertrophy","volume":"20","author":"Huusko","year":"2012","journal-title":"Mol. Ther."},{"key":"2021113011215288700_B82","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jacc.2015.04.071","article-title":"Intracoronary cytoprotective gene therapy","volume":"66","author":"Woitek","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011215288700_B83","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000033971.56802.C5","article-title":"Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs","author":"Emanueli","year":"2002","journal-title":"Circulation"},{"key":"2021113011215288700_B84","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"key":"2021113011215288700_B85","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1161\/CIRCRESAHA.109.210088","article-title":"Nerve growth factor promotes cardiac repair following myocardial infarction","volume":"106","author":"Meloni","year":"2010","journal-title":"Circ. Res."},{"key":"2021113011215288700_B86","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2337\/db11-0763","article-title":"Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice","volume":"61","author":"Meloni","year":"2012","journal-title":"Diabetes"},{"key":"2021113011215288700_B87","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCRESAHA.115.303632","article-title":"Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model","volume":"115","author":"Lin","year":"2014","journal-title":"Circ. Res."},{"key":"2021113011215288700_B88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1910073116","article-title":"A single combination gene therapy treats multiple age-related diseases","author":"Davidsohn","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2021113011215288700_B89","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1161\/01.CIR.103.14.1893","article-title":"Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction","volume":"103","author":"Li","year":"2001","journal-title":"Circulation"},{"key":"2021113011215288700_B90","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/sj.gt.3302250","article-title":"Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival","volume":"11","author":"Agrawal","year":"2004","journal-title":"Gene Ther."},{"key":"2021113011215288700_B91","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s00125-017-4232-4","article-title":"CTRP3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats","volume":"60","author":"Ma","year":"2017","journal-title":"Diabetologia"},{"key":"2021113011215288700_B92","doi-asserted-by":"publisher","first-page":"H48","DOI":"10.1152\/ajpheart.00741.2006","article-title":"Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction","volume":"293","author":"Liu","year":"2007","journal-title":"Am J Physiol-Heart Circ Physiol."},{"key":"2021113011215288700_B93","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jacc.2015.04.064","article-title":"Heme oxygenase-1 gene therapy provides cardioprotection via control of post-ischemic inflammation","volume":"66","author":"Hinkel","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113011215288700_B94","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1840","article-title":"Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF -1\/CXCR4 signalling pathway","author":"Dang","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"2021113011215288700_B95","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz459","article-title":"Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism","author":"Puca","year":"2019","journal-title":"Eur. Heart J."},{"key":"2021113011215288700_B96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/mt.2015.176","article-title":"AAV6-mediated cardiac-specific overexpression of ribonucleotide reductase enhances myocardial contractility","volume":"24","author":"Kolwicz","year":"2016","journal-title":"Mol. Ther."},{"key":"2021113011215288700_B97","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ejhf.270","article-title":"Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure","volume":"17","author":"Kadota","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"2021113011215288700_B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2019.06.006","article-title":"Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate","author":"Kolwicz","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"2021113011215288700_B99","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/eurheartj\/ehr447","article-title":"AAV6.\u03b2ARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model","volume":"34","author":"Raake","year":"2013","journal-title":"Eur. Heart J."},{"key":"2021113011215288700_B100","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/01.CIR.0000125521.40985.28","article-title":"Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts","volume":"109","author":"Williams","year":"2004","journal-title":"Circulation"},{"key":"2021113011215288700_B101","doi-asserted-by":"publisher","first-page":"720.e3","DOI":"10.1016\/j.jtcvs.2011.08.048","article-title":"AAV6-\u03b2ARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve","volume":"143","author":"Katz","year":"2012","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"2021113011215288700_B102","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/nature05815","article-title":"Cycling of O-linked \u03b2-N-acetylglucosamine on nucleocytoplasmic proteins","volume":"446","author":"Hart","year":"2007","journal-title":"Nature"},{"key":"2021113011215288700_B103","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy566.5213","article-title":"Manipulation of cardiac O-GlcNAc modification alters cardiac function and remodelling in the setting of diabetic cardiomyopathy","volume":"39","author":"Prakoso","year":"2018","journal-title":"Eur. Heart J."},{"key":"2021113011215288700_B104","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab043","article-title":"Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart","author":"Prakoso","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"2021113011215288700_B105","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/nm1671","article-title":"Pim-1 regulates cardiomyocyte survival downstream of Akt","volume":"13","author":"Muraski","year":"2007","journal-title":"Nat. Med."},{"key":"2021113011215288700_B106","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.110.239111","article-title":"Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling","volume":"108","author":"Katare","year":"2011","journal-title":"Circ. Res."},{"key":"2021113011215288700_B107","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCHEARTFAILURE.112.966622","article-title":"Phosphoinositide 3-kinase p110\u03b1 is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction","volume":"5","author":"Weeks","year":"2012","journal-title":"Circ Heart Fail."},{"key":"2021113011215288700_B108","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1042\/CS20170063","article-title":"Phosphoinositide 3-kinase (p110\u03b1) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction","volume":"131","author":"Prakoso","year":"2017","journal-title":"Clin. Sci. Lond. Engl. 1979"},{"key":"2021113011215288700_B109","doi-asserted-by":"publisher","first-page":"H840","DOI":"10.1152\/ajpheart.00632.2019","article-title":"Gene therapy targeting cardiac phosphoinositide 3-kinase (p110\u03b1) attenuates cardiac remodeling in type 2 diabetes","volume":"318","author":"Prakoso","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011215288700_B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0684-1","article-title":"Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides","volume":"17","author":"Ghosh","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113011215288700_B111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/JAHA.113.000078","article-title":"Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling","volume":"2","author":"Karakikes","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"2021113011215288700_B112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0767-z","article-title":"MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin","volume":"17","author":"Dai","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113011215288700_B113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0811-7","article-title":"MiR-30c\/PGC-1\u03b2 protects against diabetic cardiomyopathy via PPAR\u03b1","volume":"18","author":"Yin","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113011215288700_B114","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1161\/CIRCRESAHA.119.314898","article-title":"Nuclear miR-320 mediates diabetes-induced cardiac dysfunction by activating transcription of fatty acid metabolic genes to cause lipotoxicity in the heart","volume":"125","author":"Li","year":"2019","journal-title":"Circ. Res."},{"key":"2021113011215288700_B115","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/hum.2015.018","article-title":"The current and future landscape of SERCA gene therapy for heart Failure: a clinical perspective","volume":"26","author":"Hayward","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"2021113011215288700_B116","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial","volume":"15","author":"Jaski","year":"2009","journal-title":"J. Card. Fail."},{"key":"2021113011215288700_B117","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet North Am. Ed."},{"key":"2021113011215288700_B118","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol."},{"key":"2021113011215288700_B119","doi-asserted-by":"publisher","first-page":"38797","DOI":"10.1074\/jbc.M405701200","article-title":"Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3","volume":"279","author":"Gao","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021113011215288700_B120","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbrc.2009.04.110","article-title":"Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6","volume":"384","author":"Gao","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113011215288700_B121","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ahj.2018.04.005","article-title":"Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial","volume":"201","author":"Penny","year":"2018","journal-title":"Am. Heart J."},{"key":"2021113011215288700_B122","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1161\/CIRCRESAHA.120.315855","article-title":"Gene therapy for the heart lessons learned and future perspectives","volume":"126","author":"Cannat\u00e0","year":"2020","journal-title":"Circ. Res."},{"key":"2021113011215288700_B123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene. Ther. Methods"},{"key":"2021113011215288700_B124","doi-asserted-by":"publisher","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2021113011215288700_B125","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.omtm.2019.01.003","article-title":"Novel chimeric gene therapy vectors based on adeno-associated virus and four different mammalian bocaviruses","volume":"12","author":"Fakhiri","year":"2019","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"2021113011215288700_B126","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"2021113011215288700_B127","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/hum.2018.021","article-title":"Severe toxicity in nonhuman primates and piglets with systemic high-dose administration of adeno-associated virus serotype 9-like vectors: putting patients first","volume":"29","author":"Flotte","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"2021113011215288700_B128","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer Ad- p53 (Gendicine): 12 Years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"2021113011215288700_B129","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41587-019-0194-z","article-title":"Gene therapy's next installment","volume":"37","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"2021113011215288700_B130","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41587-020-0706-x","article-title":"First oral SMA drug","volume":"38","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"2021113011215288700_B131","article-title":"Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates","author":"Zabaleta","year":"2021","journal-title":"bioRxiv"},{"key":"2021113011215288700_B132","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Cl\u00e9ment","year":"2016","journal-title":"Mol. Ther. - Methods Clin. Dev."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/11\/1369\/913147\/cs-2021-0052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/11\/1369\/913147\/cs-2021-0052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:18:36Z","timestamp":1638274716000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/135\/11\/1369\/228860\/Adeno-associated-viral-AAV-vector-mediated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":132,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,6,11]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20210052","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6]]},"published":{"date-parts":[[2021,6]]}}}